Altocor (lovastatin) Extended-Release Tablets
Company: Andrx
Approval Status: Approved June 2002
Treatment for: Hypercholesterolemia
Areas: Cardiology/Vascular Diseases
| General Information | Clinical Results | Side Effects | Mechanism of Action | Additional Information |
General Information
From 25 to 30 percent of American adults have been told at one time they have high cholesterol levels.
Clinical Results
The approval of Altocor is supported by results from a multi-center placebo-controlled trial including 365 subjects. Altocor was shown to reduce total and LDL cholesterol levels and triglycerides and increase HDL cholesterol in subjects with hypercholesterolemia. Response was observed after four weeks of treatment and was maintained with continuation of therapy for up to six months. Altocor performed significantly superior to placebo.Side Effects
Adverse events associated with the use of Altocor (lovastatin) may include (but are not limited to) the following:- Nausea
- Abdominal pain
- Insomnia
- Dyspepsia
- Headache
- Asthenia
- Myalgia
Mechanism of Action
Altocor (lovastatin) is a HMG-CoA reductase inhibitor product that utilizes Andrx's proprietary SCOT technology to achieve sustained blood levels of the active drug.Additional Information
For additional information on Altocor, please visit Andrx Corporation.The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.



